PubRank

Guillermina Lozano

Author PubWeight™ 132.89‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004 8.18
2 Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004 7.22
3 Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003 4.96
4 Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 2003 3.61
5 The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008 3.17
6 MDM2, an introduction. Mol Cancer Res 2003 2.87
7 Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem 2002 2.68
8 Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 2003 2.52
9 p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012 2.04
10 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 2009 2.00
11 Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep 2007 1.96
12 A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011 1.95
13 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol 2003 1.93
14 Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013 1.86
15 Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A 2006 1.82
16 Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol 2005 1.79
17 Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol 2006 1.76
18 Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A 2002 1.72
19 Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 2003 1.68
20 Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell 2011 1.67
21 An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 2007 1.64
22 Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol 2007 1.64
23 Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Mol Cell Biol 2007 1.58
24 p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One 2008 1.55
25 Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest 2011 1.54
26 Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A 2011 1.51
27 A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 2010 1.49
28 Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res 2006 1.47
29 Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol 2004 1.44
30 p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci U S A 2006 1.41
31 Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One 2009 1.39
32 RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. Carcinogenesis 2003 1.37
33 Distinct roles of Mdm2 and Mdm4 in red cell production. Blood 2006 1.36
34 Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol 2006 1.35
35 Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res 2012 1.33
36 Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res 2003 1.32
37 The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity 2010 1.31
38 Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res 2008 1.27
39 Multiple stress signals activate mutant p53 in vivo. Cancer Res 2011 1.27
40 Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res 2010 1.23
41 Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 2011 1.21
42 Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation 2007 1.21
43 p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res 2010 1.21
44 Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell 2010 1.21
45 EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res 2008 1.17
46 High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol 2007 1.17
47 The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood 2012 1.16
48 Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathol 2010 1.15
49 Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis 2009 1.15
50 Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis 2002 1.14
51 p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res 2010 1.12
52 The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev 2013 1.11
53 Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene 2002 1.09
54 p21 stability: linking chaperones to a cell cycle checkpoint. Cancer Cell 2005 1.06
55 Li-Fraumeni syndrome: a p53 family affair. Cell Cycle 2005 1.05
56 E2F3 is a mediator of DNA damage-induced apoptosis. Mol Cell Biol 2009 1.04
57 HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol 2006 1.00
58 Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma. Sarcoma 2010 0.99
59 The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat 2014 0.97
60 Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. Mutat Res 2003 0.96
61 p53 and MDM2: antagonists or partners in crime? Cancer Cell 2009 0.96
62 Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome 2007 0.94
63 ASPP2 suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63. Proc Natl Acad Sci U S A 2013 0.94
64 Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. Differentiation 2009 0.92
65 Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One 2010 0.91
66 The Many Faces of MDM2 Binding Partners. Genes Cancer 2012 0.90
67 Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene 2004 0.89
68 Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle 2013 0.88
69 The ups and downs of p53 regulation in hematopoietic stem cells. Cell Cycle 2011 0.88
70 Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res 2005 0.88
71 Tissue-specific and age-dependent effects of global Mdm2 loss. J Pathol 2014 0.87
72 MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Cancer Lett 2005 0.86
73 Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome. Hum Genet 2011 0.85
74 The p53 family grows old. Genes Dev 2012 0.84
75 Disrupting TP53 in mouse models of human cancers. Hum Mutat 2003 0.84
76 Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res 2004 0.83
77 Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland. Oncogene 2002 0.83
78 DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-β-driven epithelial-mesenchymal transition. Cancer Discov 2013 0.83
79 Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models. J Pathol 2011 0.83
80 An information-theoretic analysis of genetics, gender and age in cancer patients. PLoS One 2008 0.83
81 Germ line BAX alterations are infrequent in Li-Fraumeni syndrome. Cancer Epidemiol Biomarkers Prev 2004 0.83
82 AACR Cancer Progress Report 2012. Clin Cancer Res 2012 0.82
83 Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-β (TGF-β). J Biol Chem 2011 0.81
84 Differential gene expression profiling of aggressive and nonaggressive follicular carcinomas. Hum Pathol 2011 0.79
85 Dissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity. Oncotarget 2014 0.79
86 Model predictions of MDM2 mediated cell regulation. Cell Cycle 2004 0.77
87 A novel genetic modifier of p53, mop1, results in embryonic lethality. Mamm Genome 2004 0.77
88 You can win by losing: p53 mutations in rhabdomyosarcomas. J Pathol 2010 0.76
89 Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol 2014 0.76
90 Genome-wide association tests of inversions with application to psoriasis. Hum Genet 2014 0.76
91 Building p53. Genes Dev 2010 0.75
92 Developing genetically engineered mouse models to study tumor suppression. Curr Protoc Mouse Biol 2012 0.75
93 Che-ating death: CHE1/AATF protects from p53-mediated apoptosis. EMBO J 2012 0.75
94 Genetic mapping of a putative tumor suppressor locus that influences tumorigenesis and metastasis in mice. Genes Chromosomes Cancer 2006 0.75